Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Compass Therapeutics, Inc. (CMPX)

Compass Therapeutics updates corporate deck with COMPANION-002 data; primary endpoint met

Mixed Impact 3 of 5 other Written later

Compass Therapeutics furnished an updated corporate presentation dated July 2026 that includes data from its COMPANION-002 study of tovecimig plus paclitaxel in biliary tract cancer. The study met its primary endpoint of overall response rate (18.0% vs 5.3%) and showed a longer median progression-free survival (4.7 vs 2.6 months), but overall survival was not significantly different (8.9 vs 9.4 months) because of crossover.

Key points

  • Primary endpoint overall response rate was 18.0% for tovecimig plus paclitaxel vs 5.3% for paclitaxel alone (p=0.0228)
  • Median progression-free survival was 4.7 vs 2.6 months (HR=0.44, p<0.0001); median overall survival was 8.9 vs 9.4 months (HR=1.05, p=0.78)
  • Company plans an FDA meeting in Q3 2026 and a BLA filing in Q4 2026, with potential approval in 2027
  • Company reported $195 million in cash and marketable securities at Q1 2026, with runway into 2028

The filing

CompanyCompass Therapeutics, Inc. (CMPX)
Form8-K, current report
Filed with the SECJul 1, 2026, 5:00 PM ET
Accession number0001171843-26-004428

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.